Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 734 people in total — 369 assigned to the placebo (dummy treatment) group and 365 assigned to receive idalopirdine (at 60 mg, or 30 mg for some participants). The trial ran for 24 weeks and was primarily measuring changes in thinking and memory abilities in people with Alzheimer's disease, using a well-recognised testing scale called the ADAS-cog, where a lower score means less cognitive impairment. Secondary measurements looked at overall clinical impression of change, ability to carry out daily activities, and behavioural disturbances. The reported data shows that on the primary cognitive test (scored from 0 to 70), both groups' scores moved slightly in the direction of more impairment over the 24 weeks — the placebo group's average score changed by +0.68 points and the idalopirdine group's by +0.13 points. For the clinician's overall impression of change (scored 1–7, where 4 means "no change"), the reported averages at week 24 were 4.32 for the placebo group and 4.39 for the idalopirdine group. On the daily activities scale (0–78, where a lower score means more difficulty), both groups showed a small decline: the placebo group by −1.72 points and the idalopirdine group by −1.05 points. For behavioural disturbances (0–144, higher meaning worse), both groups showed a small improvement: −0.46 for placebo and −0.74 for idalopirdine. In the subgroup of participants who had notable anxiety symptoms at the start, the anxiety score changed by −1.93 in the placebo group and −1.52 in the idalopirdine group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 31193334) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Alzheimer's Disease Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have a caregiver who knows you well and can be relied upon to support you.
- You are living at home or in the community (not currently staying in a hospital).
- You have been diagnosed with Alzheimer's disease (AD).
- Your Alzheimer's disease is considered mild to moderate in severity.
- You are already taking a stable dose of a type of medication called an AChEI (a common type of Alzheimer's medication, such as donepezil or rivastigmine).
- If you are a woman, you either went through natural menopause at least 2 years ago, or you have had a surgical procedure meaning you cannot become pregnant.
- If you are a man, you agree to use effective contraception during the trial if your female partner could become pregnant, or you have already had a surgical procedure meaning you cannot father children.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have signs of another significant brain or nervous system condition besides Alzheimer's disease.
- You have been diagnosed with certain other mental health conditions (beyond Alzheimer's disease) as defined by a standard medical classification system (confirm with trial site).
- You have evidence of another serious significant medical illness or condition (confirm with trial site for details).
- It is expected that your current Alzheimer's medication (AChEI) may be stopped or interrupted at any point during the trial.
- You are currently taking a medication called memantine, or you have taken it within the last 2 months.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Email contact via H. Lundbeck A/S, LundbeckClinicalTrials@lundbeck.com
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 7 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Change in Cognition
Other options
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.